Pattern Computer Advances AI-Discovered Drug for Multiple Hard-to-Treat Cancers to Testing Phase
核心洞察
Pattern Computer (搜索) has developed a novel AI-discovered drug using CRISPR technology that targets a protein not expressed in healthy adult tissue but present in aggressive early-onset colorectal cancer (搜索) patients.
The company's Pattern Discovery Engine identified a genetic signature that increases colorectal cancer (搜索) risk by 200% in individuals under 45 years old, leading to both a new diagnostic tool and therapeutic target.
Initial testing will focus on early-onset colorectal cancer (搜索), with potential applications across multiple hard-to-treat cancers including ovarian, lung, breast, pancreatic, and brain cancers.
Pattern Computer (搜索) has announced the advancement of its AI-discovered drug candidate to testing phase, marking a significant milestone in computational drug discovery for multiple hard-to-treat cancers. The company developed the novel therapeutic using its proprietary Pattern Discovery Engine™ (PDE) in collaboration with the Fred Hutch Cancer Center (搜索) and the Genetics and Epidemiology of Colorectal Cancer (搜索) Consortium (GECCO (搜索)).
Novel Target Discovery Through AI Analysis
Working with genomic data from GECCO (搜索), Pattern's AI platform identified a previously unknown drug target that exhibits unique expression patterns. The target protein is not actively expressed in any adult tissue under normal conditions but is specifically expressed in a subset of individuals with aggressive and early-onset colorectal cancer (搜索) (CRC). This discovery emerged from the company's analysis of mutational signatures and single nucleotide polymorphisms (SNPs) predictive of CRC.
The Pattern Discovery Engine uncovered a novel genomic region highly predictive of early onset and aggressive CRC, revealing a genetic background that conveys a 200% increase in CRC risk for both men and women under 45 years of age. This finding addresses a critical gap in understanding early-onset colorectal cancer (搜索), which has been increasing in incidence among younger populations.
CRISPR-Based Drug Design
Pattern designed the drug candidate with genome-wide specificity for the single target using CRISPR (clustered regularly interspaced short palindromic repeats) technology. The CRISPR-Cas9 system, which was recognized with the 2020 Nobel Prize in Chemistry, enables precise modification of DNA in living organisms and has revolutionized molecular biology approaches to medicine.
The drug development process leveraged the company's novel mathematical techniques to discover complex interactions and relationships in large genomic datasets that have previously eluded detection by conventional statistical models and larger AI systems.
Diagnostic Innovation Alongside Therapeutics
In addition to the drug discovery, Pattern developed a novel risk assessment tool—a polymerase chain reaction (PCR) test that uses a combination of over 20 single mutations to assess cancer risk for individuals under 45 years of age. This diagnostic advance represents a significant improvement over current statistical models, which typically consider only one or two mutations at a time.
The identification of this 20-mutation signature was previously impossible due to the limitations of existing analytical approaches, highlighting the potential of advanced AI pattern recognition in medical diagnostics.
Broad Cancer Applications
While initial testing is being prepared for early-onset colorectal cancer (搜索), the therapeutic approach shows strong potential for applications across multiple hard-to-treat cancers. The biological mechanism underlying the drug target's importance extends to nearly all solid-state tumors, playing crucial roles in both tumor growth and metastasis.
The drug candidate may be applicable to ovarian cancer (搜索), kidney cancer, lung cancer (搜索), breast cancer (搜索), pancreatic cancer (搜索), thyroid cancer, uterine cancer, glioblastoma (搜索), glioma, leukemia (搜索), and melanoma (搜索). This broad applicability stems from the fundamental biological pathways involved in cancer progression that the AI system identified.
Clinical Development Strategy
"This is a significant achievement and a milestone for Pattern," stated Mark Anderson, Chair and CEO. "It represents a new potential colorectal cancer (搜索) drug owned entirely by Pattern that may be applicable to many hard-to-treat cancers. Pattern is combining the low risk / high reward in drug discovery with our PDE to build novel de novo drugs for multiple cancers."
Anderson emphasized the drug's potential as a combination therapy: "The drug could potentially be used in combination with current treatments to prevent cancer spread. Our goal is to develop a pan-cancer drug with little to no toxicity that blocks metastasis and reduces or eliminates tumor growth rates."
The company is actively seeking partnerships to advance its cancer drug discoveries and diagnostic tools for the world's top five cancers into clinical trials. Pattern's approach represents a shift toward computational drug discovery that can identify novel therapeutic targets and design specific interventions with reduced development risk.
Technology Platform Capabilities
Pattern Computer (搜索)'s Pattern Discovery Engine represents a next-generation AI platform that uses proprietary mathematical techniques to find complex patterns in high-order data. The system's capabilities extend beyond oncology applications, with the company applying its computational platform to challenges in extended biotech, climate science, materials science, aerospace manufacturing, veterinary medicine, and other sectors.
The successful identification of both a diagnostic tool and therapeutic target from a single study demonstrates the platform's efficiency in translating large-scale genomic data into actionable medical insights. This integrated approach to drug discovery and diagnostics could accelerate the development of precision medicine approaches for cancer treatment.